US 12,479,823 B2
Compound for use in retinal diseases
Peng Li, Shanghai (CN); Xiaolin Li, Shanghai (CN); Zhi Luo, Shanghai (CN); Haiying He, Shanghai (CN); Guoping Hu, Shanghai (CN); Jian Li, Shanghai (CN); and Shuhui Chen, Shanghai (CN)
Assigned to ZHUHAI UNITED LABORATORIES CO., LTD., Guangdong (CN)
Filed by ZHUHAI UNITED LABORATORIES CO., LTD., Guangdong (CN)
Filed on Jan. 31, 2024, as Appl. No. 18/429,297.
Application 18/429,297 is a continuation in part of application No. 17/309,611, granted, now 11,932,617, previously published as PCT/CN2019/126178, filed on Dec. 18, 2019.
Claims priority of application No. 201811550604.8 (CN), filed on Dec. 18, 2018; and application No. 201911226373.X (CN), filed on Dec. 4, 2019.
Prior Publication US 2024/0217949 A1, Jul. 4, 2024
Int. Cl. C07D 401/12 (2006.01); A61K 31/4412 (2006.01); A61K 31/4418 (2006.01); A61K 31/444 (2006.01); A61P 27/04 (2006.01); C07D 213/73 (2006.01); C07D 401/04 (2006.01); C07D 401/06 (2006.01)
CPC C07D 401/12 (2013.01) [A61K 31/4412 (2013.01); A61K 31/4418 (2013.01); A61K 31/444 (2013.01); A61P 27/04 (2018.01); C07D 213/73 (2013.01); C07D 401/04 (2013.01); C07D 401/06 (2013.01)] 12 Claims
 
1. A method for treating dry eye disease in a subject in need thereof, comprising administering a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof to the subject, wherein the compound is a compound represented by formula (II),

OG Complex Work Unit Chemistry
wherein
custom character is selected from a single bond and a double bond;
T1, T2 and T3 are each independently selected from C and CR1;
T4 is selected from N and CR1;
Ts is selected from C, CR5, and C═O;
T6 is selected from C and CR6, T7 is N; or, T6 is N, T7 is CR7;
when Ts is selected from C═O and T6 is selected from N, then custom character is selected from a single bond;
L is selected from a single bond, —O—, and —CH2—;
each R1 is independently selected from H, F, Cl, Br, I, OH, and NH2;
R5, R6 and R7 are each independently selected from H, F, Cl, Br and I.